Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.
NCT01204177
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
70
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Hepatocellular
Interventions
DRUG:
BAY86-9766 MEK Inhibitor + Sorafenib
Sponsor
Bayer